Cargando…

The Added Benefit of Opicapone When Used Early in Parkinson's Disease Patients With Levodopa-Induced Motor Fluctuations: A Post-hoc Analysis of BIPARK-I and -II

Introduction: Opicapone (OPC) was efficacious in reducing OFF-time in two pivotal trials in patients with Parkinson's disease (PD) and end-of-dose motor fluctuations (BIPARK-I and -II). Post-hoc analyses of these trials evaluated the efficacy of OPC following pre-defined segmentation of the wid...

Descripción completa

Detalles Bibliográficos
Autores principales: Rocha, José-Francisco, Ebersbach, Georg, Lees, Andrew, Tolosa, Eduardo, Ferreira, Joaquim J., Poewe, Werner, Rascol, Olivier, Stocchi, Fabrizio, Antonini, Angelo, Magalhães, Diogo, Gama, Helena, Soares-da-Silva, Patrício
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8603564/
https://www.ncbi.nlm.nih.gov/pubmed/34803891
http://dx.doi.org/10.3389/fneur.2021.754016
_version_ 1784601790569775104
author Rocha, José-Francisco
Ebersbach, Georg
Lees, Andrew
Tolosa, Eduardo
Ferreira, Joaquim J.
Poewe, Werner
Rascol, Olivier
Stocchi, Fabrizio
Antonini, Angelo
Magalhães, Diogo
Gama, Helena
Soares-da-Silva, Patrício
author_facet Rocha, José-Francisco
Ebersbach, Georg
Lees, Andrew
Tolosa, Eduardo
Ferreira, Joaquim J.
Poewe, Werner
Rascol, Olivier
Stocchi, Fabrizio
Antonini, Angelo
Magalhães, Diogo
Gama, Helena
Soares-da-Silva, Patrício
author_sort Rocha, José-Francisco
collection PubMed
description Introduction: Opicapone (OPC) was efficacious in reducing OFF-time in two pivotal trials in patients with Parkinson's disease (PD) and end-of-dose motor fluctuations (BIPARK-I and -II). Post-hoc analyses of these trials evaluated the efficacy of OPC following pre-defined segmentation of the wide spectrum of motor fluctuations in PD. Methods: Data from matching treatment arms in BIPARK-I and -II were combined for the placebo (PLC) and OPC 50-mg groups, and exploratory post-hoc analyses were performed to investigate the efficacy of OPC 50 mg vs. PLC in subgroups of patients who were in “earlier” vs. “later” stages of both their disease course (e.g., duration of PD <6 years vs. ≥6 years) and levodopa treatment pathway (e.g., number of daily levodopa intakes <4 vs. ≥4). Efficacy variables included changes from baseline in absolute OFF-time and total ON-time. Results: The Full Analysis Set included 517 patients (PLC, n = 255; OPC 50 mg, n = 262). OPC 50 mg was significantly more effective than PLC in reducing OFF-time and increasing ON-time in the majority of subgroup analyses (p < 0.05). Moreover, patients in “earlier” stages of both their disease course and levodopa treatment pathway experienced numerically greater efficacy when using OPC 50 mg, in comparison with those in “later” stages. Conclusion: OPC 50 mg was efficacious over the whole trajectory of motor fluctuation evolution in PD patients. There was also a signal for enhanced efficacy in patients who were earlier vs. later in their disease course and levodopa treatment pathway.
format Online
Article
Text
id pubmed-8603564
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-86035642021-11-20 The Added Benefit of Opicapone When Used Early in Parkinson's Disease Patients With Levodopa-Induced Motor Fluctuations: A Post-hoc Analysis of BIPARK-I and -II Rocha, José-Francisco Ebersbach, Georg Lees, Andrew Tolosa, Eduardo Ferreira, Joaquim J. Poewe, Werner Rascol, Olivier Stocchi, Fabrizio Antonini, Angelo Magalhães, Diogo Gama, Helena Soares-da-Silva, Patrício Front Neurol Neurology Introduction: Opicapone (OPC) was efficacious in reducing OFF-time in two pivotal trials in patients with Parkinson's disease (PD) and end-of-dose motor fluctuations (BIPARK-I and -II). Post-hoc analyses of these trials evaluated the efficacy of OPC following pre-defined segmentation of the wide spectrum of motor fluctuations in PD. Methods: Data from matching treatment arms in BIPARK-I and -II were combined for the placebo (PLC) and OPC 50-mg groups, and exploratory post-hoc analyses were performed to investigate the efficacy of OPC 50 mg vs. PLC in subgroups of patients who were in “earlier” vs. “later” stages of both their disease course (e.g., duration of PD <6 years vs. ≥6 years) and levodopa treatment pathway (e.g., number of daily levodopa intakes <4 vs. ≥4). Efficacy variables included changes from baseline in absolute OFF-time and total ON-time. Results: The Full Analysis Set included 517 patients (PLC, n = 255; OPC 50 mg, n = 262). OPC 50 mg was significantly more effective than PLC in reducing OFF-time and increasing ON-time in the majority of subgroup analyses (p < 0.05). Moreover, patients in “earlier” stages of both their disease course and levodopa treatment pathway experienced numerically greater efficacy when using OPC 50 mg, in comparison with those in “later” stages. Conclusion: OPC 50 mg was efficacious over the whole trajectory of motor fluctuation evolution in PD patients. There was also a signal for enhanced efficacy in patients who were earlier vs. later in their disease course and levodopa treatment pathway. Frontiers Media S.A. 2021-11-05 /pmc/articles/PMC8603564/ /pubmed/34803891 http://dx.doi.org/10.3389/fneur.2021.754016 Text en Copyright © 2021 Rocha, Ebersbach, Lees, Tolosa, Ferreira, Poewe, Rascol, Stocchi, Antonini, Magalhães, Gama and Soares-da-Silva. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Neurology
Rocha, José-Francisco
Ebersbach, Georg
Lees, Andrew
Tolosa, Eduardo
Ferreira, Joaquim J.
Poewe, Werner
Rascol, Olivier
Stocchi, Fabrizio
Antonini, Angelo
Magalhães, Diogo
Gama, Helena
Soares-da-Silva, Patrício
The Added Benefit of Opicapone When Used Early in Parkinson's Disease Patients With Levodopa-Induced Motor Fluctuations: A Post-hoc Analysis of BIPARK-I and -II
title The Added Benefit of Opicapone When Used Early in Parkinson's Disease Patients With Levodopa-Induced Motor Fluctuations: A Post-hoc Analysis of BIPARK-I and -II
title_full The Added Benefit of Opicapone When Used Early in Parkinson's Disease Patients With Levodopa-Induced Motor Fluctuations: A Post-hoc Analysis of BIPARK-I and -II
title_fullStr The Added Benefit of Opicapone When Used Early in Parkinson's Disease Patients With Levodopa-Induced Motor Fluctuations: A Post-hoc Analysis of BIPARK-I and -II
title_full_unstemmed The Added Benefit of Opicapone When Used Early in Parkinson's Disease Patients With Levodopa-Induced Motor Fluctuations: A Post-hoc Analysis of BIPARK-I and -II
title_short The Added Benefit of Opicapone When Used Early in Parkinson's Disease Patients With Levodopa-Induced Motor Fluctuations: A Post-hoc Analysis of BIPARK-I and -II
title_sort added benefit of opicapone when used early in parkinson's disease patients with levodopa-induced motor fluctuations: a post-hoc analysis of bipark-i and -ii
topic Neurology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8603564/
https://www.ncbi.nlm.nih.gov/pubmed/34803891
http://dx.doi.org/10.3389/fneur.2021.754016
work_keys_str_mv AT rochajosefrancisco theaddedbenefitofopicaponewhenusedearlyinparkinsonsdiseasepatientswithlevodopainducedmotorfluctuationsaposthocanalysisofbiparkiandii
AT ebersbachgeorg theaddedbenefitofopicaponewhenusedearlyinparkinsonsdiseasepatientswithlevodopainducedmotorfluctuationsaposthocanalysisofbiparkiandii
AT leesandrew theaddedbenefitofopicaponewhenusedearlyinparkinsonsdiseasepatientswithlevodopainducedmotorfluctuationsaposthocanalysisofbiparkiandii
AT tolosaeduardo theaddedbenefitofopicaponewhenusedearlyinparkinsonsdiseasepatientswithlevodopainducedmotorfluctuationsaposthocanalysisofbiparkiandii
AT ferreirajoaquimj theaddedbenefitofopicaponewhenusedearlyinparkinsonsdiseasepatientswithlevodopainducedmotorfluctuationsaposthocanalysisofbiparkiandii
AT poewewerner theaddedbenefitofopicaponewhenusedearlyinparkinsonsdiseasepatientswithlevodopainducedmotorfluctuationsaposthocanalysisofbiparkiandii
AT rascololivier theaddedbenefitofopicaponewhenusedearlyinparkinsonsdiseasepatientswithlevodopainducedmotorfluctuationsaposthocanalysisofbiparkiandii
AT stocchifabrizio theaddedbenefitofopicaponewhenusedearlyinparkinsonsdiseasepatientswithlevodopainducedmotorfluctuationsaposthocanalysisofbiparkiandii
AT antoniniangelo theaddedbenefitofopicaponewhenusedearlyinparkinsonsdiseasepatientswithlevodopainducedmotorfluctuationsaposthocanalysisofbiparkiandii
AT magalhaesdiogo theaddedbenefitofopicaponewhenusedearlyinparkinsonsdiseasepatientswithlevodopainducedmotorfluctuationsaposthocanalysisofbiparkiandii
AT gamahelena theaddedbenefitofopicaponewhenusedearlyinparkinsonsdiseasepatientswithlevodopainducedmotorfluctuationsaposthocanalysisofbiparkiandii
AT soaresdasilvapatricio theaddedbenefitofopicaponewhenusedearlyinparkinsonsdiseasepatientswithlevodopainducedmotorfluctuationsaposthocanalysisofbiparkiandii
AT rochajosefrancisco addedbenefitofopicaponewhenusedearlyinparkinsonsdiseasepatientswithlevodopainducedmotorfluctuationsaposthocanalysisofbiparkiandii
AT ebersbachgeorg addedbenefitofopicaponewhenusedearlyinparkinsonsdiseasepatientswithlevodopainducedmotorfluctuationsaposthocanalysisofbiparkiandii
AT leesandrew addedbenefitofopicaponewhenusedearlyinparkinsonsdiseasepatientswithlevodopainducedmotorfluctuationsaposthocanalysisofbiparkiandii
AT tolosaeduardo addedbenefitofopicaponewhenusedearlyinparkinsonsdiseasepatientswithlevodopainducedmotorfluctuationsaposthocanalysisofbiparkiandii
AT ferreirajoaquimj addedbenefitofopicaponewhenusedearlyinparkinsonsdiseasepatientswithlevodopainducedmotorfluctuationsaposthocanalysisofbiparkiandii
AT poewewerner addedbenefitofopicaponewhenusedearlyinparkinsonsdiseasepatientswithlevodopainducedmotorfluctuationsaposthocanalysisofbiparkiandii
AT rascololivier addedbenefitofopicaponewhenusedearlyinparkinsonsdiseasepatientswithlevodopainducedmotorfluctuationsaposthocanalysisofbiparkiandii
AT stocchifabrizio addedbenefitofopicaponewhenusedearlyinparkinsonsdiseasepatientswithlevodopainducedmotorfluctuationsaposthocanalysisofbiparkiandii
AT antoniniangelo addedbenefitofopicaponewhenusedearlyinparkinsonsdiseasepatientswithlevodopainducedmotorfluctuationsaposthocanalysisofbiparkiandii
AT magalhaesdiogo addedbenefitofopicaponewhenusedearlyinparkinsonsdiseasepatientswithlevodopainducedmotorfluctuationsaposthocanalysisofbiparkiandii
AT gamahelena addedbenefitofopicaponewhenusedearlyinparkinsonsdiseasepatientswithlevodopainducedmotorfluctuationsaposthocanalysisofbiparkiandii
AT soaresdasilvapatricio addedbenefitofopicaponewhenusedearlyinparkinsonsdiseasepatientswithlevodopainducedmotorfluctuationsaposthocanalysisofbiparkiandii